Page 1

NEWS RELEASE Contacts : Media Troy Kirkpatrick VP , Public Relations 858.617.2361 troy.kirkpatrick@bd.com ● BD Advancing the world of health Investors Kristen M. Stewart , CFA SVP , Strategy & Investor Relations 201.847.5378 kristen.stewart@bd.com BD ANNOUNCES SECOND FISCAL QUARTER RESULTS ; REAFFIRMS FISCAL 2021 GUIDANCE Second fiscal quarter revenues of $ 4.9 billion grew 15.4 % on a reported basis . On a currency - neutral basis , revenues increased 12.2 % . BD's COVID - 19 testing sales were $ 480 million , including BD VeritorTM Plus System revenues of $ 290 million . BD's core growth led by strong growth in Medication Delivery Solutions ( up 10.4 % ) , Pharmaceutical Systems ( up 15.4 % ) , and Biosciences ( up 16.3 % ) on a reported basis . Second fiscal quarter GAAP diluted earnings per share ( EPS ) increased 77.4 % year - over - year to $ 0.94 . Adjusted EPS increased 25.1 % year - over - year to $ 3.19 . BD is reaffirming its fiscal 2021 revenue growth and adjusted EPS guidance . Franklin Lakes , NJ ( May 6 , 2021 ) - BD ( Becton , Dickinson and Company ) ( NYSE : BDX ) , a leading global medical technology company , today reported quarterly revenues of $ 4.9 billion for the second fiscal quarter ended March 31 , 2021. This represents an increase of 15.4 % over the prior - year period on a reported basis and was driven by the contribution of BD's COVID - 19 diagnostic revenues , which totaled $ 480 million , as well as solid core business growth . On a currency - neutral basis , revenues increased 12.2 % . " We delivered strong revenue , earnings per share , and cash flow growth in the quarter and achieved several important milestones , most notably the recent submission of our 510 ( k ) premarket notification for the BD AlarisTM System to the United States Food and Drug Administration , " said Tom Polen , Chairman , CEO and president of BD . " We also continued our essential role in the fight against COVID - 19 by developing innovative diagnostic solutions and supplying the frontline with products urgently needed for patient care and vaccination -all while continuing to advance our growth and reinvestment initiatives . With our announced intention to spin off our diabetes business to shareholders , we are taking another bold step in our BD 2025 strategy , which focuses on unleashing our growth potential , delivering innovations for our customers , empowering our associates , and creating value for our shareholders . "